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Identity 
Inheritance: Sporadic occurrence, with possible cases 
of autosomal dominant inheritance 
Clinics 
Phenotype and clinics 
Clinical presentation usually occurs between 2nd an
3rd decades; most cases at puberty. 
- Exceptional cases in younger children; youngest 
example at 6 months of age. 
Male pseudohermaphroditism; phenotypically female 
patients presenting with amenorrhea. 
- XY karyotype:  
- Streak (dysgenetic) gonads with gonadoblastoma. 
- Normal external female genitalia; clitoris enlargement 
and ambiguous genitalia may be present. 
- Small uterus (often with an inactive/atrophic 
endometrium) and fallopian tubes. 
Nephrotic syndrome with slowly progressing renal 
disease, resulting in end-stage renal failure. 
- Focal and segmental glomerulosclerosis; in later 
stages of renal disease, only chronic, nonspecific 
findings may be present in kidney biopsy. 
XX karyotype: patients with less severe phenotype, 
frequently not clinically identified as FS. 
- Normal and functioning female genitalia. 
- Clinically present only with renal disease. 
Neoplastic risk 
Gonadoblastomas are present in virtually all XY 
patients; usually bilateral. 
Germ cell tumors (dysgerminomas) may arise from 
gonadoblastoma within dysgenetic gonads. 
Wilms tumors are exceptional, and in these cases th 
diagnosis of FS is controversial (differential diagnosis 
with Denys-Drash syndrome; vide infra). 
Treatment 
Prophylactic bilateral gonadectomy (may be 
laparoscopic if there is no evidence of overgrowth by a 
germ cell tumor); hysterectomy is not necessary. 
The renal disease is usually steroid-resistant, requi ing 
dialysis and renal transplantation. 
Chemotherapy may be needed in cases with germ cell 
tumors. 
In XY patients, menstruation can be induced with 
cyclic hormone replacement therapy; there are report d 
cases of successful pregnancy following in vitro 
fertilization procedures in these patients. 
Evolution 
The end-stage renal disease is usually the major cause 
of morbidity in FS patients. The focal and segmental 
glomerulosclerosis progresses slowly (often for more 
than 10 years) and leads to terminal renal failure, 
requiring dialysis therapy and renal transplantation 
which can result in complications and increased 
morbidity. There are limited data regarding the clini al 
outcome after renal transplantation in these patients. 
The occurrence of germ cell neoplasia in FS patients 
can affect their prognosis. However, there is no 
evidence that FS-associated germ cell tumors have a 
different clinical outcome in comparison with sporadic 
tumors. 
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Figure 1. Surgical appearance of the internal genitalia in a patient with Frasier syndrome. A) Small but normally shaped uterus. B) A 
streak gonad is seen at the tip of the surgical instrument (courtesy of Dr. Masoud Azodi, Yale University School of Medicine). 
 
 
Figure 2. A-B: Kidney biopsy showing focal and segmental glomerulosclerosis (FSGS). A: Masson trichrome stain (400X). B: Semi-thin 
section stained with toluidine blue (400X). C-D: Gonadectomy specimens. C: Streak gonad with gonadoblastoma (H & E 40X). D: 
Gonadoblastoma nodule displaying Call-Exner body-like structures, surrounded by Leydig-like cells (H & E 200X). E-F: Histological 
aspect of dysgerminoma arising in gonadoblastoma. E: Gonadectomy specimen showing both, gonadoblastoma and dysgerminoma (H 
& E 100X). F: Peritoneal metastasis of dysgerminoma (H & E 200X). 
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Genes involved and Proteins 
WT1 (Wilms Tumor 1) 
Location: 11p13 
DNA/RNA 
Description: 10 exons; spans approximately 50 kb. 
Encodes 4 zinc finger domains. 
Transcription: Alternative splicing in two different sites 
(exons 5 and 9) leads to variable insertion of exon 5 
and/or insertion of 9 nucleotides in exon 9, resulting in 
transcription of four different isoforms. 
Protein 
Description: Transcription factor: contains 4 zinc finger 
domains. 
Four different isoforms, ranging from 52 to 54 kDa 
(429-449 aminoacids). 
Alternative splicing in exon 9: variable insertion of
aminoacids lysine (K), threonine (T) and serine (S)
between 3rd and 4th zinc fingers results in either +KTS 
or -KTS isoforms. 
Expression: During embryonal life, the WT1 protein is 
mainly expressed in the metanephros and developing 
kidney, gonadal ridges, coelomic surfaces, heart, 
spleen, liver, thymus, uterus and muscles of the 
abdominal wall. 
An adequate ratio of +KTS/-KTS expression is 
essential for the wild type function of WT1. 
Localisation: Nuclear (transcription factor function). 
Function: WT1 functions mainly as a transcription 
factor, with many different downstream target genes; a 
post-transcriptional regulatory function of some target 
mRNAs has been also proposed. 
In mammalian embryos, expression of the -KTS 
isoform induces gonadal ridge formation through 
proliferation of the coelomic epithelium, resulting in 
the bipotential gonad. 
In XY individuals, expression of the +KTS isoform 
will activate the transcription of the SRY gene located 
on Y chromosome, which induces the expression of 
anti-mYllerian hormone by the developing Sertoli cels. 
Expression of the anti-mYllerian hormone in the 
developing testis results in formation of seminiferous 
cords, allowing sex-specific gonadal development, ad
regression of mYllerian structures (which give rise to 
the female genitalia). 
During early kidney development in mammal embryos, 
the -KTS isoform promotes proliferation of the 
primordial mesenchyme, epithelial-mesenchymal 
interactions and ureteric bud branching. In later phases 
of kidney development, expression of +KTS leads to 
differentiation of podocytes and glomerular capillaries. 
Mutations 
Most of the WT1 gene mutations in FS are located in 
positions 2, 4, 5 or 6 of the second splice donor site in 
intron 9. 
These mutations lead to a decrease in the +KTS 
isoform, affecting the zinc fingers' DNA binding 
affinity. 
A decrease in +KTS is in keeping with the phenotype 
observed in FS, in which there seems to be a defect in 
antimüllerian hormone expression resulting in 
abnormal genital development in XY individuals. Also, 
defective expression of this isoform could explain the
glomerular lesion observed in FS. 
To be noted 
The classical clinical picture of FS is that of a 
phenotypically female adolescent patient presenting 
with either amenorrhea or nephrotic syndrome, or both. 
However, the clinical presentation may be atypical, 
with cases occurring at earlier ages or in XX patients, 
resulting in the presence of only renal disease. These 
atypical cases must be differentiated from sporadic 
forms of nephrotic syndrome, and from other entities 
such as Denys-Drash syndrome (DDS), which is also 
related to WT1 mutations but features rapidly 
progressive renal disease at earlier ages. It is important 
to establish a differential diagnosis between FS and
DDS, since they carry different tumor risks requiring 
specific clinical management: while in FS there is an 
increased risk for the development of gonadal 
neoplasms, in DDS there is an increased risk for the 
development of Wilms tumors; while FS mutations 
affect a splice site in intron 9, DDS results from 
missense mutations in exons 8 and 9 of WT1. In these 
atypical cases, molecular analysis may be of extreme 
importance to reveal the specific genetic defect in the 
WT1 gene, allowing an accurate diagnosis. 
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